PROLONGED SURVIVAL IN PATIENTS WITH BETA-THALASSEMIA MAJOR TREATED WITH DEFEROXAMINE

被引:108
作者
EHLERS, KH
GIARDINA, PJ
LESSER, ML
ENGLE, MA
HILGARTNER, MW
机构
[1] N SHORE UNIV HOSP, DIV BIOSTAT, MANHASSET, NY 11030 USA
[2] CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT PEDIAT, DIV CARDIOL, NEW YORK, NY 10021 USA
关键词
D O I
10.1016/S0022-3476(05)83374-8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
To determine whether survival of patients with beta-thalassemia major has been prolonged by management that utilizes hypertransfusion and chelation with deferoxamine, we analyzed longevity by the Kaplan-Meier product-limit method. Group 1 patients (n = 71) followed between 1960 and 1976 with a low-transfusion regimen (pretransfusion hemoglobin level 7 to 8 gm/dl) and no chelation had an estimated median age of survival of 17.4 years, whereas it was 31.0 years for group 2 subjects (n = 80), who began hypertransfusion between 1976 and 1978 (pretransfusion hemoglobin level 10.5 to 11.5 gm/dl) and chelation with deferoxamine (20 to 60 mg/kg per day) (p < 0.0001). For 70 patients who were treated with hypertransfusion and deferoxamine, we had data to calculate the ratio of total milligrams of transfusional iron to cumulative grams of deferoxamine. The 24 patients who died had a total iron burden of > 1.05 gm/kg; the ratio for them exceeded 31. These patients were characterized by poor compliance with chelation or by late start of therapy, with inability to receive enough deferoxamine before death. Death was preceded by arrhythmia requiring therapy in all but one, and by cardiac failure in all. Of 41 similarly iron-loaded survivors, 33 had a ratio of < 31; only three had an arrhythmia, and five had cardiac failure. We conclude that treatment with deferoxamine, when used in amounts proportional to iron burden, delayed cardiac complications and improved longevity.
引用
收藏
页码:540 / 545
页数:6
相关论文
共 25 条
  • [1] IRON STATE AND HEPATIC-DISEASE IN PATIENTS WITH THALASSEMIA MAJOR, TREATED WITH LONG-TERM SUBCUTANEOUS DESFERRIOXAMINE
    ALDOURI, MA
    WONKE, B
    HOFFBRAND, AV
    FLYNN, DM
    LAULICHT, M
    FENTON, LA
    SCHEUER, PJ
    KIBBLER, CC
    ALLWOOD, CA
    BROWN, D
    THOMAS, HC
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1987, 40 (11) : 1353 - 1359
  • [2] LONG-TERM CHELATION THERAPY IN THALASSEMIA MAJOR - EFFECT ON LIVER IRON CONCENTRATION, LIVER HISTOLOGY, AND CLINICAL PROGRESS
    BARRY, M
    FLYNN, DM
    LETSKY, EA
    RISDON, RA
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1974, 2 (5909): : 16 - 20
  • [3] BRITTENHAM G, 1988, BLOOD S, V72, pA56
  • [4] RAPID REMOVAL OF EXCESSIVE IRON WITH DAILY, HIGH-DOSE INTRAVENOUS CHELATION-THERAPY
    COHEN, AR
    MIZANIN, J
    SCHWARTZ, E
    [J]. JOURNAL OF PEDIATRICS, 1989, 115 (01) : 151 - 155
  • [5] Ehlers K H, 1980, Ann N Y Acad Sci, V344, P397
  • [6] EHLERS KH, 1980, CARDIOVASC CLIN, V11, P171
  • [7] LATE CARDIAC COMPLICATIONS OF CHRONIC SEVERE REFRACTORY ANEMIA WITH HEMOCHROMATOSIS
    ENGLE, MA
    ERLANDSON, M
    SMITH, CH
    [J]. CIRCULATION, 1964, 30 (05) : 698 - &
  • [8] STUDIES ON CONGENITAL HEMOLYTIC SYNDROMES .4. GASTROINTESTINAL ABSORPTION OF IRON
    ERLANDSON, ME
    WEHMAN, J
    WALDEN, B
    SMITH, CH
    HILGARTNER, MW
    STERN, G
    [J]. BLOOD, 1962, 19 (03) : 359 - &
  • [9] EARLY LEFT-VENTRICULAR DYSFUNCTION AND CHELATION-THERAPY IN THALASSEMIA MAJOR
    FREEMAN, AP
    GILES, RW
    BERDOUKAS, VA
    WALSH, WF
    CHOY, D
    MURRAY, PC
    [J]. ANNALS OF INTERNAL MEDICINE, 1983, 99 (04) : 450 - 454
  • [10] CHELATION-THERAPY IN BETA-THALASSEMIA MAJOR .3. THE ROLE OF SPLENECTOMY IN ACHIEVING IRON BALANCE
    GRAZIANO, JH
    PIOMELLI, S
    HILGARTNER, M
    GIARDINA, P
    KARPATKIN, M
    ANDREW, M
    LOIACONO, N
    SEAMAN, C
    [J]. JOURNAL OF PEDIATRICS, 1981, 99 (05) : 695 - 699